** Shares in Ambu AMBUb.CO rise 3%, paring earlier gains
of as much as 10%, after the Danish maker of single-use
endoscopy solutions hiked its full-year outlook and posted
preliminary Q2 financials
** In a statement published after market close on Wednesday
the company said it sees 2023/24 organic revenue growth of
10-12% (earlier guidance 7-10%) and underlying EBIT margin of
10-12 (earlier guidance 8-10%)
** Free cash flow expectations was raised to DKK +370
million from the previous DKK +270 million
** Ambu reported preliminary results for Q2 with revenue of
DKK 1,367 million ($196.87 million) compared to DKK 1,189
million year ago, with organic revenue growth of 15.5%
** Its prelim EBIT before special items was DKK 194 million,
up from DKK 46 million the previous year
** The share, up 9.79% YTD, is among best performers on
pan-Europan STOXX .STOXX index
($1 = 6.9436 Danish crowns)
(Reporting by Elviira Luoma)
((Elviira.luoma@thomsonreuters.com))